venglustat: Clinical Trials

16 trials of venglustat, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

10 completed, 4 active not recruiting, 2 terminated. 8 Phase 1, 5 Phase 2, 4 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	8	Completed 8
Phase 2	5	Completed 2, Terminated 2, Active not recruiting 1
Phase 3	4	Active not recruiting 3, Terminated 1

Follow venglustat: new trials by email Literature Review of venglustat trials Research Report on venglustat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function Venglustat (GZ402671) - Hepatic Function Abnormal	Phase 1	Completed	Sanofi	26	2023-01-18	2025-09-15
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828) - Fabry Disease	Phase 3	Active not recruiting	Sanofi	104	2022-05-03	2026-06-24
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 Venglustat, imiglucerase - Gaucher's Disease Type III	Phase 3	Active not recruiting	Sanofi	43	2022-04-18	2026-07-13
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Venglustat (GZ402671), Placebo - Fabry Disease	Phase 3	Active not recruiting	Sanofi	122	2022-03-11	2026-10-13
A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants Venglustat - Healthy Volunteers	Phase 1	Completed	Sanofi	65	2020-06-23	2024-05-17
A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants Venglustat - Healthy Volunteers	Phase 1	Completed	Sanofi	9	2020-06-18	2024-05-17
Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects venglustat - Disorders of Sphingolipid Metabolism, Healthy Volunteers	Phase 1	Completed	Genzyme, a Sanofi Company	6	2020-05-26	2025-09-17
Effect of Venglustat in Patients With Renal Impairment Venglustat GZ/SAR402671 - Healthy Volunteers, Polycystic Kidney, Autosomal Dominant	Phase 1	Completed	Genzyme, a Sanofi Company	24	2018-10-05	2022-04-25
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Venglustat, Placebo - Polycystic Kidney, Autosomal Dominant	Phase 2 / Phase 3	Terminated	Genzyme, a Sanofi Company	478	2018-10-04	2023-02-03
A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants Venglustat, Itraconazole - Healthy Volunteers	Phase 1	Completed	Genzyme, a Sanofi Company	8	2018-08-16	2024-05-20
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension venglustat (GZ402671), imiglucerase - Gaucher Disease Type 1, Gaucher Disease Type 3	Phase 2	Active not recruiting	Genzyme, a Sanofi Company	12	2017-01-04	2026-07-10
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation venglustat GZ/SAR402671, Placebo - Parkinson's Disease	Phase 2	Terminated	Genzyme, a Sanofi Company	273	2016-12-15	2022-05-24
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease GZ/SAR402671 - Fabry Disease	Phase 2	Completed	Genzyme, a Sanofi Company	8	2015-07-07	2021-03-23
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease GZ/SAR402671 - Fabry Disease	Phase 2	Completed	Genzyme, a Sanofi Company	11	2014-11-01	2019-12-17
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers Genz-682452, Placebo - Healthy	Phase 1	Completed	Genzyme, a Sanofi Company	36	2012-10-01	2014-03-19
Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men Genz-682452, Placebo - Healthy Volunteer	Phase 1	Completed	Genzyme, a Sanofi Company	63	2012-08-01	2014-03-19

Conditions studied

Sponsors

Countries

Results publications

NIH funding